Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201,…

Posted: Published on October 6th, 2022

This post was added by Alex Diaz-Granados

Connect Biopharma Holdings Limited

Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT,tomorrow, Tuesday, October 4

SAN DIEGO and TAICANG, SUZHOU, China, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a company developing therapeutics for T cell-driven inflammatory diseases, today announced it will report topline results for its pivotal trial in China of lead candidate, CBP-201, in patients with moderate-to-severe atopic dermatitis (AD). Following the press release, the Company will host a webcast and conference call at 5:30 a.m. PDT to discuss these results.

The news release will be posted to the investor relations section of Connect Biopharmas website at:https://investors.connectbiopharm.com/investors.

About Connect Biopharma Holdings Limited Connect Biopharma is a U.S. and China-based clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases through the development of therapies derived from T cell research. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Companys lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4R) in development for the treatment of atopic dermatitis and asthma. The Companys second most advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis (UC). The Companys third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with AD. For more information, please visit: https://www.connectbiopharm.com/

Story continues

IR/PR CONTACTS: Ina McGuinness T: +1 (805) 427-1372 imcguinness@connectpharm.com

Follow this link:
Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201,...

Related Posts
This entry was posted in Ulcerative Colitis. Bookmark the permalink.

Comments are closed.